ERRγ mediates tamoxifen resistance in novel models of invasive lobular breast cancer

Cancer Research

Volumn 68, Issue 21, 2008, Pages 8908-8917

  Riggins, Rebecca B ^a   Lan, Jennifer P J ^a   Klimach, Uwe ^a   Zwart, Alan ^a   Cavalli, Luciane R ^a   Haddad, Bassem R ^a   Chen, Li ^b   Gong, Ting ^b   Xuan, Jianhua ^b   Ethier, Stephen P ^c   Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b State University   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RELATED RECEPTOR GAMMA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; 4-HYDROXYTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESRRG PROTEIN, HUMAN; TAMOXIFEN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CARCINOMA CELL; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; INHIBITION KINETICS; INVASIVE LOBULAR BREAST CANCER; LCCTAM CELL; MBA MB 134 VI CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SUM44 CELL; BREAST TUMOR; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; LUNG CARCINOMA; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, LOBULAR; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSCRIPTION FACTOR AP-1;

EID: 55349138386     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2669     Document Type: Article

References (59)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003;289:1421-4.
3. Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 2007;14:549-67.
4. Jimeno A, Amador ML, Gonzalez-Cortijo L, et al. Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. Cancer 2004;100:1833-42.
5. Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006;17:1228-33.
6. Wenzel C, Bartsch R, Hussian D, et al. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat 2007;104:109-14.
7. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001;CD000486.
8. Smith DB, Howell A, Wagstaff J. Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol 1987;23:979-82.
9. Rakha EA, El-Sayed ME, Powe DG, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008;44:73-83.
10. Clarke R, Skaar TC, Bouker KB, et al. Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 2001;76:71-84.
11. Clarke R, Liu MC, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003;22:7316-39.
12. Riggins R, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 2005;71:201-37.
13. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to Tamoxifen resistance. Cancer Lett 2007;256:1-24.
14. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004;83:249-89.
15. Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL. Differential isolation of normal liminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res 1993;53:627-35.
16. van de WM, Barker N, Harkes IC, et al. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res 2001;61:278-84.
17. Cowley SM, Parker MG. A comparison of transcriptional activation by ER α and ER β. J Steroid Biochem Mol Biol 1999;69:165-75.
18. Vanacker JM, Bonnelye E, Chopin-Delannoy S, Delmarre C, Cavailles V, Laudet V. Transcriptional activities of the orphan nuclear receptor ERR α (estrogen receptor-related receptor-α). Mol Endocrinol 1999;13:764-73.
19. Hong H, Yang L, Stallcup MR. Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3. J Biol Chem 1999;274:22618-26.
20. Riggins R, Zwart A, Nehra N, Agarwal P, Clarke R. The NFkB inhibitor parthenolide restores ICI 182,780 (Faslodex; Fulvestrant)-induced apoptosis in antiestrogen resistant breast cancer cells. Mol Cancer Ther 2005;4:33-41.
21. Riggins RB, Thomas KS, Ta HQ, et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 2006;66:7007-15.
22. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
23. Brünner N, Frandsen TL, Holst-Hansen C, et al. MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 1993;53:3229-32.
24. Figueiredo BC, Stratakis CA, Sandrini R, et al. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab 1999;84:1116-21.
25. Gomez BP, Riggins RB, Shajahan AN, et al. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J 2007;21:4013-27.
26. Ellis M, Davis N, Coop A, et al. Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res 2002;8:1155-66.
27. Liu A, Zhang Y, Gehan E, Clarke R. Block principal component analysis with application to gene microarray data classification. Stat Med 2002;21:3465-74.
28. Bouker KB, Skaar TC, Fernandez DR, et al. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (Faslodex, Fulvestrant). Cancer Res 2004;64:4030-9.
29. Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the Breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
30. Forozan F, Veldman R, Ammerman CA, et al. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 1999;81:1328-34.
31. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 1993;53:283-90.
32. Horard B, Vanacker JM. Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J Mol Endocrinol 2003;31:349-57.
33. Giguère V. To ERR in the estrogen pathway. Trends Endocrinol Metab 2002;13:220-5.
34. Ariazi EA, Jordan VC. Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr Top Med Chem 2006;6:203-15.
35. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE. Estrogen-related receptor {α}1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol Cancer Res 2007;5:71-85.
36. Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor α and estrogen-related receptor γ associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 2002;62:6510-8.
37. Reiner GC, Katzenellenbogen BS. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells. Cancer Res 1986;46:1124-31.
38. Reis-Filho JS, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12:6652-62.
39. Greschik H, Wurtz JM, Sanglier S, et al. Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol Cell 2002;9:303-13.
40. Greschik H, Flaig R, Renaud JP, Moras D. Structural basis for the deactivation of the estrogen-related receptor γ by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. J Biol Chem 2004;279:33639-46.
41. Holzberg D, Knight CG, Ttrich-Breiholz O, et al. Disruption of the c-JUN-JNK complex by a cell-permeable peptide containing the c-JUN δ domain induces apoptosis and affects a distinct set of interleukin-1-induced inflammatory genes. J Biol Chem 2003;278:40213-23.
42. Huppunen J, Wohlfahrt G, Aarnisalo P. Requirements for transcriptional regulation by the orphan nuclear receptor ERRγ. Mol Cell Endocrinol 2004;219:151-60.
43. Matys V, Kel-Margoulis OV, Fricke E, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006;34:D108-10.
44. Kel AE, Gossling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E. MATCH: a tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 2003;31:3576-9.
45. Mascaro C, Nadal A, Hegardt FG, Marrero PF, Haro D. Contribution of steroidogenic factor 1 to the regulation of cholesterol synthesis1. Biochem J 2000;350 Pt 3:785-90.
46. Ortiz JA, Gil-Gomez G, Casaroli-Marano RP, Vilaro S, Hegardt FG, Haro D. Transfection of the ketogenic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme A synthase cDNA into Mev-1 cells corrects their auxotrophy for mevalonate. J Biol Chem 1994;269:28523-6.
47. Wakil SJ, Stoops JK, Joshi VC. Fatty acid synthesis and its regulation. Annu Rev Biochem 1983;52:537-79.
48. Kallinowskil F, Davel S, Vaupell P, Baessler KH, Wagner K. Glucose, lactate, and ketone body utilization by human mammary carcinomas in vivo. Adv Exp Med Biol 1985;191:763-73.
49. Duncan RE, El-Sohemy A, Archer MC. Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development. Mol Nutr Food Res 2005;49:93-100.
50. Lupu R, Menendez JA. Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators? Endocrinology 2006;147:4056-66.
51. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 1996;7:351-9.
52. Zhou Y, Yau C, Gray JW, et al. Enhanced NF κ B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007;7:59.
53. Johnston SR, Lu B, Scott GK, et al. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 1999;5:251-6.
54. Schiff R, Reddy P, Ahotupa M, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000;92:1926-34.
55. Alaynick WA, Kondo RP, Xie W, et al. ERRγ directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 2007;6:13-24.
56. Montero J, Morales A, Llacuna L, et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res 2008;68:5246-56.
57. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
58. Schuetz CS, Bonin M, Clare SE, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006;66:5278-86.
59. Charafe-Jauffret E, Monville F, Bertucci F, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer 2007;121:1779-85.